DOCSLIB.ORG

ICD10 Diagnoses FY2018 AHD.Com

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ICD10 Diagnoses FY2018 AHD.com A020 Salmonella enteritis A5217 General paresis B372 Candidiasis of skin and nail A040 Enteropathogenic Escherichia coli A523 Neurosyphilis, unspecified B373 Candidiasis of vulva and vagina infection A528 Late syphilis, latent B3741 Candidal cystitis and urethritis A044 Other intestinal Escherichia coli A530 Latent syphilis, unspecified as early or B3749 Other urogenital candidiasis infections late B376 Candidal endocarditis A045 Campylobacter enteritis A539 Syphilis, unspecified B377 Candidal sepsis A046 Enteritis due to Yersinia enterocolitica A599 Trichomoniasis, unspecified B3781 Candidal esophagitis A047 Enterocolitis due to Clostridium difficile A6000 Herpesviral infection of urogenital B3789 Other sites of candidiasis A048 Other specified bacterial intestinal system, unspecified B379 Candidiasis, unspecified infections A6002 Herpesviral infection of other male B380 Acute pulmonary coccidioidomycosis A049 Bacterial intestinal infection, genital organs B381 Chronic pulmonary coccidioidomycosis unspecified A630 Anogenital (venereal) warts B382 Pulmonary coccidioidomycosis, A059 Bacterial foodborne intoxication, A6920 Lyme disease, unspecified unspecified unspecified A7740 Ehrlichiosis, unspecified B387 Disseminated coccidioidomycosis A080 Rotaviral enteritis A7749 Other ehrlichiosis B389 Coccidioidomycosis, unspecified A0811 Acute gastroenteropathy due to A879 Viral meningitis, unspecified B399 Histoplasmosis, unspecified Norwalk agent A938 Other specified arthropod-borne viral B440 Invasive pulmonary aspergillosis A0839 Other viral enteritis fevers B441 Other pulmonary aspergillosis A084 Viral intestinal infection, unspecified B001 Herpesviral vesicular dermatitis B4481 Allergic bronchopulmonary aspergillosis A088 Other specified intestinal infections B002 Herpesviral gingivostomatitis and B449 Aspergillosis, unspecified A09 Infectious gastroenteritis and colitis, pharyngotonsillitis B451 Cerebral cryptococcosis unspecified B004 Herpesviral encephalitis B460 Pulmonary mucormycosis A150 Tuberculosis of lung B0052 Herpesviral keratitis B488 Other specified mycoses A159 Respiratory tuberculosis unspecified B0089 Other herpesviral infection B49 Unspecified mycosis A310 Pulmonary mycobacterial infection B009 Herpesviral infection, unspecified B589 Toxoplasmosis, unspecified A312 Dissem mycobacterium avium- B0223 Postherpetic polyneuropathy B59 Pneumocystosis intracellulare complex (DMAC) B0229 Other postherpetic nervous system B600 Babesiosis A318 Other mycobacterial infections involvement B850 Pediculosis due to Pediculus humanus A319 Mycobacterial infection, unspecified B0230 Zoster ocular disease, unspecified capitis A363 Cutaneous diphtheria B027 Disseminated zoster B852 Pediculosis, unspecified A400 Sepsis due to streptococcus, group A B028 Zoster with other complications B86 Scabies A401 Sepsis due to streptococcus, group B B029 Zoster without complications B888 Other specified infestations A403 Sepsis due to Streptococcus B1081 Human herpesvirus 6 infection B91 Sequelae of poliomyelitis pneumoniae B159 Hepatitis A without hepatic coma B948 Sequelae of oth infectious and parasitic A408 Other streptococcal sepsis B169 Acute hepatitis B w/o delta-agent and diseases A409 Streptococcal sepsis, unspecified without hepatic coma B950 Streptococcus, group A, causing A4101 Sepsis due to Methicillin susceptible B1710 Acute hepatitis C without hepatic coma diseases classd elswhr Staphylococcus aureus B179 Acute viral hepatitis, unspecified B951 Streptococcus, group B, causing A4102 Sepsis due to Methicillin resistant B181 Chronic viral hepatitis B without delta- diseases classd elswhr Staphylococcus aureus agent B952 Enterococcus as the cause of diseases A411 Sepsis due to other specified B182 Chronic viral hepatitis C classified elsewhere staphylococcus B1910 Unspecified viral hepatitis B without B953 Streptococcus pneumoniae causing A412 Sepsis due to unspecified hepatic coma diseases classd elswhr staphylococcus B1920 Unspecified viral hepatitis C without B954 Oth streptococcus as the cause of A414 Sepsis due to anaerobes hepatic coma diseases classd elswhr A4150 Gram-negative sepsis, unspecified B20 Human immunodeficiency virus [HIV] B955 Unsp streptococcus as the cause of A4151 Sepsis due to Escherichia coli [E. coli] disease diseases classd elswhr A4152 Sepsis due to Pseudomonas B250 Cytomegaloviral pneumonitis B9561 Methicillin suscep staph infct causing A4153 Sepsis due to Serratia B258 Other cytomegaloviral diseases dis classd elswhr A4159 Other Gram-negative sepsis B259 Cytomegaloviral disease, unspecified B9562 Methicillin resis staph infct causing A4181 Sepsis due to Enterococcus B2700 Gammaherpesviral mononucleosis diseases classd elswhr A4189 Other specified sepsis without complication B957 Oth staphylococcus as the cause of A419 Sepsis, unspecified organism B309 Viral conjunctivitis, unspecified diseases classd elswhr A430 Pulmonary nocardiosis B341 Enterovirus infection, unspecified B958 Unsp staphylococcus as the cause of A46 Erysipelas B342 Coronavirus infection, unspecified diseases classd elswhr A480 Gas gangrene B348 Other viral infections of unspecified site B960 Mycoplasma pneumoniae as the cause A481 Legionnaires' disease B349 Viral infection, unspecified of diseases classd elswhr A488 Other specified bacterial diseases B351 Tinea unguium B961 Klebsiella pneumoniae as the cause of A4901 Methicillin suscep staph infection, unsp B353 Tinea pedis diseases classd elswhr site B354 Tinea corporis B9620 Unsp Escherichia coli as the cause of A4902 Methicillin resis staph infection, unsp B356 Tinea cruris diseases classd elswhr site B358 Other dermatophytoses B9622 Oth shiga toxin E coli (STEC) causing A493 Mycoplasma infection, unspecified site B359 Dermatophytosis, unspecified diseases classd elswhr A498 Other bacterial infections of unspecified B368 Other specified superficial mycoses B9629 Oth Escherichia coli as the cause of site B369 Superficial mycosis, unspecified diseases classd elswhr A499 Bacterial infection, unspecified B370 Candidal stomatitis B963 Hemophilus influenzae as the cause of A5216 Charcot's arthropathy (tabetic) B371 Pulmonary candidiasis diseases classd elswhr ICD10 Diagnoses FY2018 AHD.com B964 Proteus (mirabilis) (morganii) causing dis C180 Malignant neoplasm of cecum C3432 Malignant neoplasm of lower lobe, left classd elswhr C181 Malignant neoplasm of appendix bronchus or lung B965 Pseudomonas (mallei) causing diseases C182 Malignant neoplasm of ascending colon C3480 Malignant neoplasm of ovrlp sites of classd elswhr C183 Malignant neoplasm of hepatic flexure unsp bronchus and lung B966 Bacteroides fragilis as the cause of C184 Malignant neoplasm of transverse colon C3481 Malignant neoplasm of ovrlp sites of diseases classd elswhr C185 Malignant neoplasm of splenic flexure right bronchus and lung B9681 Helicobacter pylori as the cause of C186 Malignant neoplasm of descending C3490 Malignant neoplasm of unsp part of diseases classd elswhr colon unsp bronchus or lung B9689 Oth bacterial agents as the cause of C187 Malignant neoplasm of sigmoid colon C3491 Malignant neoplasm of unsp part of diseases classd elswhr C189 Malignant neoplasm of colon, right bronchus or lung B970 Adenovirus as the cause of diseases unspecified C3492 Malignant neoplasm of unsp part of left classified elsewhere C19 Malignant neoplasm of rectosigmoid bronchus or lung B9710 Unsp enterovirus as the cause of junction C37 Malignant neoplasm of thymus diseases classd elswhr C20 Malignant neoplasm of rectum C4021 Malignant neoplasm of long bones of B9719 Oth enterovirus as the cause of C210 Malignant neoplasm of anus, right lower limb diseases classd elswhr unspecified C410 Malignant neoplasm of bones of skull B9729 Oth coronavirus as the cause of C211 Malignant neoplasm of anal canal and face diseases classd elswhr C220 Liver cell carcinoma C411 Malignant neoplasm of mandible B974 Respiratory syncytial virus causing C221 Intrahepatic bile duct carcinoma C412 Malignant neoplasm of vertebral diseases classd elswhr C227 Other specified carcinomas of liver column B9781 Human metapneumovirus as the cause C228 Malignant neoplasm of liver, primary, C414 Malignant neoplasm of pelvic bones, of diseases classd elswhr unspecified as to type sacrum and coccyx B9789 Oth viral agents as the cause of C229 Malig neoplasm of liver, not specified as C419 Malignant neoplasm of bone and diseases classd elswhr primary or sec articular cartilage, unsp B998 Other infectious disease C23 Malignant neoplasm of gallbladder C434 Malignant melanoma of scalp and neck B999 Unspecified infectious disease C240 Malignant neoplasm of extrahepatic bile C4359 Malignant melanoma of other part of C01 Malignant neoplasm of base of tongue duct trunk C021 Malignant neoplasm of border of C241 Malignant neoplasm of ampulla of Vater C4362 Malignant melanoma of left upper limb, tongue C249 Malignant neoplasm of biliary tract, including shoulder C029 Malignant neoplasm of tongue, unspecified C4371 Malignant melanoma of right lower unspecified C250 Malignant neoplasm of head of limb, including hip C030 Malignant neoplasm of upper gum pancreas C4372 Malignant melanoma of left lower limb, C031 Malignant neoplasm of lower gum C251 Malignant neoplasm of body of including hip C049 Malignant neoplasm of floor of mouth, pancreas C439 Malignant melanoma of skin, unspecified C252 Malignant neoplasm of tail of pancreas unspecified C060 Malignant neoplasm of cheek mucosa C253 Malignant neoplasm of pancreatic duct C44222 Squamous cell carcinoma
Recommended publications
  • Womens Health Requisition Forms

    Womens Health Requisition Forms

    PCR - WHI Implementation PLACE ON SWAB 10854 Midwest Industrial Blvd. St. Louis, MO 63132 MM DD YY Phone: (314) 200-3040 | Fax (314) 200-3042 (1) CLIA ID #26D0953866 JANE DOE v3 PCR MOLECULAR REQUISITION - WOMEN'S HEALTH INFECTION PRACTICE INFORMATION PATIENT INFORMATION *SPECIMEN INFORMATION (2) DOE JANE MM/DD/YY LAST NAME FIRST NAME DATE COLLECTED W O M E ' N S H E A L T H I F N E C T I O N SSN MM/DD/YY HH:MM AM SSN DATE OF BIRTH TIME COLLECTED REQUESTING PHYSICIAN: DR. SWAB TESTER (3) Sex: F X M (4) Diagnosis Codes X N76.0 Acute vaginitis B37.49 Other urogenital candidiasis A54.9 Gonococcal infection, unspecified N76.1 Subacute and chronic vaginitis N89.8 Other specified noninflammatory disorders of vagina A59.00 Urogenital trichomoniasis, unspecified N76.2 Acute vulvitis O99.820 Streptococcus B carrier state complicating pregnancy A64 Unspecified sexually transmitted disease N76.3 Subacute and chronic vulvitis O99.824 Streptococcus B carrier state complicating childbirth A74.9 Chlamydial infection, unspecified N76.4 Abscess of vulva B95.1 Streptococcus, group B, as the cause Z11.3 Screening for infections with a predmoninantly N76.5 Ulceration of vagina of diseases classified elsewhere sexual mode of trasmission N76.6 Ulceration of vulva Z22.330 Carrier of group B streptococcus Other: N76.81 Mucositis(ulcerative) of vagina and vulva N70.91 Salpingitis, unspecified N76.89 Other specified inflammation of vagina and vulva N70.92 Oophoritis, unspecified N95.2 Post menopausal atrophic vaginitis N71.9 Inflammatory disease of uterus, unspecified
  • N35.12 Postinfective Urethral Stricture, NEC, Female N35.811 Other

    N35.12 Postinfective Urethral Stricture, NEC, Female N35.811 Other

    N35.12 Postinfective urethral stricture, NEC, female N35.811 Other urethral stricture, male, meatal N35.812 Other urethral bulbous stricture, male N35.813 Other membranous urethral stricture, male N35.814 Other anterior urethral stricture, male, anterior N35.816 Other urethral stricture, male, overlapping sites N35.819 Other urethral stricture, male, unspecified site N35.82 Other urethral stricture, female N35.911 Unspecified urethral stricture, male, meatal N35.912 Unspecified bulbous urethral stricture, male N35.913 Unspecified membranous urethral stricture, male N35.914 Unspecified anterior urethral stricture, male N35.916 Unspecified urethral stricture, male, overlapping sites N35.919 Unspecified urethral stricture, male, unspecified site N35.92 Unspecified urethral stricture, female N36.0 Urethral fistula N36.1 Urethral diverticulum N36.2 Urethral caruncle N36.41 Hypermobility of urethra N36.42 Intrinsic sphincter deficiency (ISD) N36.43 Combined hypermobility of urethra and intrns sphincter defic N36.44 Muscular disorders of urethra N36.5 Urethral false passage N36.8 Other specified disorders of urethra N36.9 Urethral disorder, unspecified N37 Urethral disorders in diseases classified elsewhere N39.0 Urinary tract infection, site not specified N39.3 Stress incontinence (female) (male) N39.41 Urge incontinence N39.42 Incontinence without sensory awareness N39.43 Post-void dribbling N39.44 Nocturnal enuresis N39.45 Continuous leakage N39.46 Mixed incontinence N39.490 Overflow incontinence N39.491 Coital incontinence N39.492 Postural
  • Neuropsychological Testing

    Neuropsychological Testing

    Medical Coverage Policy Effective Date ............................................. 8/15/2021 Next Review Date ....................................... 8/15/2022 Coverage Policy Number .................................. 0258 Neuropsychological Testing Table of Contents Related Coverage Resources Overview .............................................................. 1 Attention-Deficit/Hyperactivity Disorder: Assessment Coverage Policy ................................................... 1 and Treatment General Background ............................................ 2 Autism Spectrum Disorder/Pervasive Developmental Medicare Coverage Determinations .................. 15 Disorders: Assessment and Treatment Coding/Billing Information .................................. 16 Cognitive Rehabilitation Lyme Disease Treatment— Antibiotic Treatment References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
  • Academy of Medical Sciences of Ukraine L. V. Gromashevskiy

    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy

    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy Institute of Epidemiology and Infektious Diseases Panasiuk Olena Leonidivna ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 14.01.13 — Infektious Diseases Kyiv — 2007 TABLE OF CONTENTS LIST OF ABBREVIATIONS USED INTRODUCTION CHAPTER 1 PRESSING ISSUES OF TREATMENT OF HERPES VIRUS INFECTIONS 1.2. Main principles of treatment of patients with herpes virus infections CHAPTER 2 MATERIALS AND STUDY METHODS 2.1. Characteristic of examined patients 2.2. Characteristic of study drug and treatment methods 2.3. Study design 2.3.1. Subjects enrollment and discontinuation criteria 2.3.2. Principles and algorithm of subjects grouping 2.3.3. Assessment of therapy efficacy 2.4. Study methods 2.4.1. Clinical method 2.4.2. Special study methods 2.4.3. Statistical method CHAPTER 3 ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 3.1. Clinical efficacy of Proteflazid 3.2. Adverse effects of therapy with Proteflazid 3.3. Interferon inducing and immunomodulatory activity of Proteflazid in subjects with herpes virus infection 3.3.1. Immunomodulatory activity of Proteflazid 3.3.2. Interferon inducing properties of Proteflazid CHAPTER 4 LONG-TERM RESULTS OF TREATMENT OF HERPES VIRUS INFECTION 4.1. Anti-relapse efficacy of Proteflazid CONCLUSIONS PRACTICAL GUIDELINES REFERENCES List of abbreviations used NK (CD16) — natural killer cells NSE — neurospecific enolase ME — meningoencerebritis ANAD — acyclic nucleoside antiviral drugs AB — antibody
  • Diagnostic Tests for Vaginosis/Vaginitis

    Diagnostic Tests for Vaginosis/Vaginitis

    Alberta Heritage Foundation for Medical Research Diagnostic tests for vaginosis/vaginitis Christa Harstall and Paula Corabian October 1998 HTA12 Diagnostic tests for vaginosis/vaginitis Christa Harstall and Paula Corabian October 1998 © Copyight Alberta Heritage Foundation for Medical Research, 1998 This Health Technology Assessment Report has been prepared on the basis of available information of which the Foundation is aware from public literature and expert opinion, and attempts to be current to the date of publication. The report has been externally reviewed. Additional information and comments relative to the Report are welcome, and should be sent to: Director, Health Technology Assessment Alberta Heritage Foundation for Medical Research 3125 Manulife Place, 10180 - 101 Street Edmonton Alberta T5J 3S4 CANADA Tel: 403-423-5727, Fax: 403-429-3509 This study is based, in part, on data provided by Alberta Health. The interpretation of the data in the report is that of the authors and does not necessarily represent the views of the Government of Alberta. ISBN 1-896956-15-7 Alberta's health technology assessment program has been established under the Health Research Collaboration Agreement between the Alberta Heritage Foundation for Medical Research and the Alberta Health Ministry. Acknowledgements The Alberta Heritage Foundation for Medical Research is most grateful to the following persons for their comments on the draft report and for provision of information. The views expressed in the final report are those of the Foundation. Dr. Jane Ballantine, Section of General Practice, Calgary Dr. Deirdre L. Church, Microbiology, Calgary Laboratory Services, Calgary Dr. Nestor N. Demianczuk, Royal Alexandra Hospital, Edmonton Dr.
  • SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1

    SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1

    The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis,
  • 30-Year Trends in Admission

    30-Year Trends in Admission

    Iro, M. A., Sadarangani, M., Goldacre, R., Nickless, A., Pollard, A., & Goldacre, M. J. (2017). 30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(17)30114-7 Peer reviewed version License (if available): CC BY-NC-ND Link to published version (if available): 10.1016/S1473-3099(17)30114-7 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S1473-3099(17)30114-7 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Thirty-year trends in admission rates for childhood encephalitis in England and impact of improved diagnostics and measles and mumps vaccination– a population based observational study Mildred A Iro (MBBS) 1, Manish Sadarangani (DPhil) 1,2, Raphael Goldacre (MSc)3, Alecia Nickless (MSc) 4, Prof Andrew J Pollard* (FMedSci) 1, Prof Michael J Goldacre* (FFPH) 3 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical
  • Remarks on Pelvic Peritonitis and Pelvic Cellulitis, with Illustrative Cases

    Remarks on Pelvic Peritonitis and Pelvic Cellulitis, with Illustrative Cases

    Article IV.- Remarks on Pelvic Peritonitis and Pelvic Cellulitis, with Illustrative Cases. By Lauchlan Aitken, M.D. Rather moie than a year ago there appeared from the pen of a well- known of this a gynecologist city very able monograph on the two forms of pelvic inflammation whose names head this article; and it cannot have escaped the recollection of the reader that Dr M. Dun- can, adopting the nomenclature first proposed by Yirchow, has used on his different terms title-page1 than those older appellations I still to retain. Under these propose ^ circumstances I feel at to compelled least to attempt justify my preference for the original names: and I trust to be able to show that are they preferable to, and less con- others that fusing than, any have as yet been proposed, even though we cannot consider them absolutely perfect. 1 Treatise on A Practical Perimetritis and Parametritis (Edin. 1869). 1870.] DR LAUCI1LAN AITKEN ON PELVIC FERITONITIS, ETC. 889 Passing over, then, such terms as 'periuterine cellulitis or phleg- mons periuterins as bad compounds ; others, as inflammation of the broad ligaments, as too limited in meaning ; and others, again, as engorgement periutdrin, as only indicating one of the stages of the affection,?I shall endeavour as succinctly as possible to state my reasons for preferring the older names to those proposed by Virchow. ls?. The two Greek prepositions, peri and para, are employed somewhat arbitrarily to indicate inflammatory processes which are essentially distinct. I say arbitrarily, because I am not aware that para has been generally employed in the form of a compound to ex- press inflammation of the cellular tissue elsewhere.1 By those who remember that the cellular tissue not only separates the serous membrane from the uterus at that part where the cervix and body of the organ meet, but is even abundant there,2 perimetritis might readily be taken to indicate one of the varieties, though indeed not a in for which very common one, of pelvic cellulitis?a variety, fact, the term perimetric cellulitis has been proposed.
  • Supplementary Appendix

    Supplementary Appendix

    Supplementary appendix Sipilä PN, Heikkilä N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, Suominen S, Väänänen A, Koskinen A, Nyberg ST, Pentti J, Strandberg TE, Kivimäki M. Hospital-treated infectious diseases and the risk of incident dementia: multicohort study with replication in the UK Biobank CONTENTS eFigure 1. Selection of participants in the study............................................................................... 2 eMethods 1. Study cohorts and data collection ................................................................................ 3 The Finnish Public Sector study (FPS)......................................................................................... 3 The Health and Social Support study (HeSSup) ........................................................................... 4 The Still Working study (STW) ................................................................................................... 5 The UK Biobank ......................................................................................................................... 5 eMethods 2. Proportionality of hazards ........................................................................................... 7 eFigure 2. Visualisation of hazard ratios over time using exponentiated scaled Schoenfeld residuals ....................................................................................................................................................... 8 eFigure 3. Dementia follow-up .....................................................................................................
  • The Relative Risk

    The Relative Risk

    Clinical Expert Series Pelvic Inflammatory Disease David E. Soper, MD Obstet Gynecol 2010;116(2) ACCME Accreditation The American College of Obstetricians and Gynecologists (ACOG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. (Continuing medical education credit for “Pelvic Inflammatory Disease” will be available through August 2013.) AMA PRA Category 1 CreditTM and ACOG Cognate Credit The American College of Obstetricians and Gynecologists (ACOG) designates this educational activity for a maximum of 2 AMA PRA Category 1 CreditsTM or up to a maximum of 2 Category 1 ACOG cognate credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Disclosure Statement Current guidelines state that continuing medical education (CME) providers must ensure that CME activities are free from the control of any commercial interest. All authors, reviewers, and contributors have disclosed to the College all relevant financial relationships with any commercial interests. The authors, reviewers, and contributors declare that neither they nor any business associate nor any member of their immediate families has financial interest or other relationships with any manufacturer of products or any providers of services discussed in this program. Any conflicts have been resolved through group and outside review of all content. Before submitting this form, please print a completed copy as confirmation of your program participation. ACOG Fellows: To obtain credits, complete and return this form by clicking on “Submit” at the bottom of the page. Credit will be automatically recorded upon receipt and online transcripts will be updated twice monthly.
  • BQI Icare HIV/AIDS

    BQI Icare HIV/AIDS

    RESOURCE AND PATIENT MANAGEMENT SYSTEM iCare Population Management GUI (BQI) HIV/AIDS Management User Manual Version 2.6 July 2017 Office of Information Technology (OIT) Division of Information Technology iCare Population Management GUI (BQI) Version 2.6 Table of Contents 1.0 Introduction ......................................................................................................... 1 1.1 Key Functional Features .......................................................................... 1 1.2 Sensitive Patient Data ............................................................................. 2 2.0 Patient Management ........................................................................................... 3 2.1 Data Specifically Related to HIV/AIDS ..................................................... 3 2.2 Search for and View a Patient Record ..................................................... 6 2.2.1 Using a Panel ........................................................................................ 6 2.2.2 Using Quick Search ............................................................................... 7 2.3 Displaying Care Management as Default Tab ......................................... 8 2.4 Add/Edit Care Management Data ............................................................ 8 2.4.1 Entering Data on the General Area ....................................................... 9 2.4.2 Entering Data on the Partner Notification Area .................................... 11 2.4.3 Entering Data on the Antiretroviral
  • ITDRD Book.Book

    ITDRD Book.Book

    2 0 2 DESK REFERENCE 1 optum360coding.com Seamless shopping starts here. Diagnoses ICD-10-CM for Reference Desk Coders’ Coders’ Desk Reference The redesigned optum360coding.com offers new conveniences and the same great coding resources you’ve always trusted for a convenient, seamless shopping experience. for ICD-10-CM Diagnoses Device-friendly shopping Product information at Clinical descriptions with answers to your your fingertips Effortlessly view our new website on toughest ICD-10-CM coding questions any device — desktop, tablet or Find product details and features — smartphone — optum360coding.com including item number, ISBN number and is with you wherever you go. availability date — quickly and easily. Intuitive product organization Streamlined checkout Optum360 coding products are View and edit your cart, ship to multiple organized by category so you can find recipients, add payment information, what you need quickly and easily. assign a PO number and complete your purchase — all on one page. Sign in to check out View all your account Signing in prior to checkout ensures information your online and offline transactions are seamlessly linked to the same account for Get immediate access to your order and your convenience. Don’t have an online invoice history, track shipments, renew a account? It’s easy to create one — visit product, create a wish list or update your optum360coding.com/register. contact information. Visit optum360coding.com © 2020 Optum360, LLC. All rights reserved. WF2305592 04/20 SAMPLE ITDRD21/ITDRD Made in the USA